• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat

    6/6/24 2:45:57 PM ET
    $ASNS
    $FRGT
    $ICU
    $REPL
    Telecommunications Equipment
    Telecommunications
    Professional Services
    Consumer Discretionary
    Get the next $ASNS alert in real time by email

    U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling around 0.1% on Thursday.

    The Dow traded up 0.06% to 38,830.40 while the NASDAQ fell 0.16% to 17,160.31. The S&P 500 also fell, dropping, 0.12% to 5,347.42.       .

    Check This Out: Wall Street’s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields

    Leading and Lagging Sectors

    Consumer discretionary shares rose by 0.8% on Thursday.

    In trading on Thursday, utilities shares fell by 0.8%.

    Top Headline

    The J. M. Smucker Company (NYSE:SJM) shares gained around 5% on Thursday after the company posted upbeat quarterly earnings.

    The company reported a fourth-quarter FY24 sales decline of 1.3% year-on-year to $2.21 billion, missing the analyst consensus estimate of $2.24 billion. Adjusted EPS of $2.66 beat the analyst consensus estimate of $2.33, according to data from Benzinga Pro.

    Equities Trading UP
                           

    • Replimune Group, Inc. (NASDAQ:REPL) shares shot up 24% to $6.91 as the company announced positive topline primary analysis data by Independent Central Review from IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma.
    • Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) got a boost, surging 23% to $6.20 after Cycle Pharmaceuticals confirmed that it made a proposal to buy the company.
    • Freight Technologies, Inc. (NASDAQ:FRGT) shares were also up, gaining 30% to $0.8221 after the company said it added 26 new customers and 149 new carriers in 2024.

    Equities Trading DOWN

    • Actelis Networks, Inc. (NASDAQ:ASNS) shares dropped 46% to $2.00 after the company announced an agreement for the immediate exercise of certain outstanding warrants for gross proceeds of $3 million.
    • Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) were down 39% to $0.2171. SeaStar Medical announced a 25-for-1 reverse stock split.
    • Ventyx Biosciences, Inc. (NASDAQ:VTYX) was down, falling 41% to $3.13 after the company announced preclinical data for its CNS-penetrant NLRP3 inhibitor VTX3232 in murine diet-induced obesity models.

    Also Check This Out: Top 4 Industrials Stocks That Could Lead To Your Biggest Gains This Quarter

    Commodities

    In commodity news, oil traded up 2% to $75.53 while gold traded up 0.6% at $2,390.50.

    Silver traded up 4.3% to $31.375 on Thursday, while copper rose 1.5% to $4.6765.

    Euro zone

    European shares were higher today. The eurozone's STOXX 600 rose 0.66%, Germany's DAX gained 0.41% and France's CAC 40 rose 0.42%. Spain's IBEX 35 Index rose 0.80%, while London's FTSE 100 rose 0.47%.

    The ECB cut the three key interest rates by 25 basis points, in line with market estimates. Retail sales in the Eurozone fell 0.5% month-over-month in April compared to revised 0.7% gain in March, while Eurozone construction PMI increased to 42.9 in May from 41.9 in the prior month.

    The S&P Global UK construction PMI climbed to 54.7 in May, recording the highest level since May 2022, while The France construction PMI increased to 43.4 in May from 41.5 a month ago. Factory orders in Germany fell by 0.2% month-over-month for April.

    Asia Pacific Markets

    Asian markets closed mostly higher on Thursday, with Japan's Nikkei gaining 0.55%, China's Composite Index falling 0.54%, Hong Kong's Hang Seng Index gaining 0.28% and India's S&P BSE Sensex gaining 0.7%.

    Australia’s trade surplus on goods increased to AUD 6.55 billion in April 2024 compared to a revised AUD 4.84 billion surplus in the prior month. Exports of goods from Australia fell 2.5% to a 28-month low level of AUD 43.32 billion in April, while imports of goods dipped by 7.2% to a three-month low level of AUD 36.77 billion.

    Economics

    • U.S. initial jobless claims rose by 8,000 to 229,000 in the week ending June 1, compared to market estimates of 220,000.
    • The trade deficit in the U.S. increased to $74.6 billion in April versus a revised $68.6 billion gap in March.
    • Unit labor costs in the nonfarm business sector rose by an annualized 4% in the first quarter compared to a revised 2.8% fall in the previous period.
    • Nonfarm business sector labor productivity increased by 0.2% in the first quarter compared to preliminary reading of a 0.3% gain.
    • U.S. natural-gas supplies increased 98 billion cubic feet during the week ended May 31, compared to market estimates of an 89 billion cubic feet gain.

    Now Read This: Alphabet, Walmart And 2 Other Stocks Insiders Are Selling

    Get the next $ASNS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASNS
    $FRGT
    $ICU
    $REPL

    CompanyDatePrice TargetRatingAnalyst
    The J.M. Smucker Company
    $SJM
    3/11/2026$145.00Mkt Perform → Outperform
    Bernstein
    Vanda Pharmaceuticals Inc.
    $VNDA
    3/5/2026$18.00Buy
    Truist
    The J.M. Smucker Company
    $SJM
    2/23/2026$130.00Neutral → Buy
    BofA Securities
    The J.M. Smucker Company
    $SJM
    1/16/2026$105.00Overweight → Equal-Weight
    Morgan Stanley
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    Ventyx Biosciences Inc.
    $VTYX
    11/5/2025$18.00Neutral → Buy
    H.C. Wainwright
    Replimune Group Inc.
    $REPL
    11/3/2025$11.00Underperform → Market Perform
    BMO Capital Markets
    Replimune Group Inc.
    $REPL
    10/27/2025$12.00Neutral → Buy
    H.C. Wainwright
    More analyst ratings

    $ASNS
    $FRGT
    $ICU
    $REPL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Amin Tarang bought $99,801 worth of shares (880 units at $113.41), increasing direct ownership by 23% to 4,705 units (SEC Form 4)

    4 - J M SMUCKER Co (0000091419) (Issuer)

    3/3/26 4:41:12 PM ET
    $SJM
    Packaged Foods
    Consumer Staples

    Director Baird Jennifer A bought $987 worth of shares (4,200 units at $0.24), increasing direct ownership by 13% to 36,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/22/25 6:55:38 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Messinger Michael bought $5,098 worth of shares (14,500 units at $0.35), increasing direct ownership by 483% to 17,500 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/11/25 6:49:59 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ASNS
    $FRGT
    $ICU
    $REPL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASNS
    $FRGT
    $ICU
    $REPL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods

    WASHINGTON, March 19, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a leader in innovative drug development and a vocal advocate for reducing unnecessary animal testing, today voiced serious concerns over the U.S. Food and Drug Administration (FDA)'s new draft guidance, "General Considerations for the Use of New Approach Methodologies in Drug Development," released March 18, 2026, by the Center for Drug Evaluation and Research (CDER). The FDA's draft guidance aims to support the use of New Approach Methodologies (NAMs)—advanced non-animal tools like in v

    3/19/26 4:34:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actelis Networks Reports 2025 Financial Results Highlighted by Strong Fourth Quarter Rebound

    SUNNYVALE, Calif, March 18, 2026 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ:ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid-deployment networking solutions for IoT and broadband applications, today reported its financial results for the full year ended December 31, 2025, and provided business and corporate updates. Revenues for the fourth quarter of 2025 were approximately $1.4 million, representing an increase of 113% from $0.64 million in the third quarter of 2025. For the full year 2025, revenues were $3.7 million, compared to $7.8 million in the prior year. The decrease was primarily driven by two large deals in 2024 that did not repeat in 2025. In

    3/18/26 5:15:00 PM ET
    $ASNS
    Telecommunications Equipment
    Telecommunications

    SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

    DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, March 25, 2026, at 4:30 p.m. ET / 2:30 p.m. MT  Webcast:The live webcast and replay can be found here.  Register for the call:Preregistration is required to attend the live call and can be accessed h

    3/18/26 4:05:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ASNS
    $FRGT
    $ICU
    $REPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Freudenthaler Paul D

    3 - Freight Technologies, Inc. (0001687542) (Issuer)

    3/19/26 6:43:56 AM ET
    $FRGT
    Professional Services
    Consumer Discretionary

    SEC Form 3 filed by new insider Gonzalez Leon Jose Andres

    3 - Freight Technologies, Inc. (0001687542) (Issuer)

    3/19/26 6:40:35 AM ET
    $FRGT
    Professional Services
    Consumer Discretionary

    SEC Form 3 filed by new insider Selgas Javier

    3 - Freight Technologies, Inc. (0001687542) (Issuer)

    3/19/26 6:38:04 AM ET
    $FRGT
    Professional Services
    Consumer Discretionary

    $ASNS
    $FRGT
    $ICU
    $REPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    J.M. Smucker upgraded by Bernstein with a new price target

    Bernstein upgraded J.M. Smucker from Mkt Perform to Outperform and set a new price target of $145.00

    3/11/26 8:29:05 AM ET
    $SJM
    Packaged Foods
    Consumer Staples

    Truist initiated coverage on Vanda Pharma with a new price target

    Truist initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    3/5/26 8:32:16 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    J.M. Smucker upgraded by BofA Securities with a new price target

    BofA Securities upgraded J.M. Smucker from Neutral to Buy and set a new price target of $130.00

    2/23/26 8:29:47 AM ET
    $SJM
    Packaged Foods
    Consumer Staples

    $ASNS
    $FRGT
    $ICU
    $REPL
    SEC Filings

    View All

    SEC Form 6-K filed by Freight Technologies Inc.

    6-K - Freight Technologies, Inc. (0001687542) (Filer)

    3/19/26 5:28:08 PM ET
    $FRGT
    Professional Services
    Consumer Discretionary

    SEC Form 8-K filed by Actelis Networks Inc.

    8-K - ACTELIS NETWORKS INC (0001141284) (Filer)

    3/18/26 5:24:10 PM ET
    $ASNS
    Telecommunications Equipment
    Telecommunications

    SEC Form 10-K filed by Actelis Networks Inc.

    10-K - ACTELIS NETWORKS INC (0001141284) (Filer)

    3/18/26 5:22:27 PM ET
    $ASNS
    Telecommunications Equipment
    Telecommunications

    $ASNS
    $FRGT
    $ICU
    $REPL
    Leadership Updates

    Live Leadership Updates

    View All

    The J.M. Smucker Co. Appoints Two New Independent Directors

    NRG Energy CFO Bruce Chung and Experienced Consumer Industry Executive David Singer to Join Board of DirectorsBoard Appointments Follow Constructive Engagement with Elliott Investment ManagementORRVILLE, Ohio, Feb. 26, 2026 /PRNewswire/ -- The J.M. Smucker Co. today announced it has appointed Woo-Sung (Bruce) Chung and David Singer to its Board of Directors, effective April 15, 2026. With the addition of Chung and Singer, the Board will comprise 11 directors, 10 of whom are independent, and all of whom are focused on advancing the work underway to drive continued growth, enhanced profitability, and disciplined capital allocation for the Company.The appointments follow constructive engagement

    2/26/26 7:00:00 AM ET
    $SJM
    Packaged Foods
    Consumer Staples

    La Rosa Holdings Corp. Announces Appointment of Nicholas Adler as Chairman of the Board and Chairman of the Compensation Committee

    Celebration, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) ("La Rosa" or the "Company"), a real estate and PropTech company, today announced that the Company's Board of Directors (the "Board") has appointed Mr. Nicholas Adler as a member of the Board, effective December 29, 2025. Upon his appointment, Mr. Adler was also named Chairman of the Board, Chairman of the Compensation Committee, and a member of both the Audit Committee and the Nominating and Corporate Governance Committee. Additionally, on December 29, 2025, Mr. Siamack Alavi notified the Board of his resignation as a director of the Company, effective immediately. Mr. Alavi also stepped down from hi

    12/30/25 8:30:00 AM ET
    $FRGT
    $LRHC
    Professional Services
    Consumer Discretionary
    Real Estate
    Finance

    Freight Technologies Announces the Commercial Launch of Zayren - AI-Powered Freight Rate Prediction & Carrier Matching Platform

    HOUSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Freight Technologies, Inc. (NASDAQ:FRGT, "Fr8Tech" or the "Company")), a logistics management innovation company offering a diverse portfolio of technology-driven solutions, today announced the commercial launch of Zayren, an artificial intelligence ("AI") based, machine learning pricing-prediction tool and carrier-matching platform designed specifically for cross-border and domestic over-the-road ("OTR") freight shipments across Mexico and the United States. Developed by Fr8Tech's in-house AI Lab or the Artificial Intelligence Lab, Zayren provides real-time freight-rate predictions, enabling shippers and brokers to access instant pricing insight

    11/19/25 9:00:00 AM ET
    $FRGT
    Professional Services
    Consumer Discretionary

    $ASNS
    $FRGT
    $ICU
    $REPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 7:54:08 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SeaStar Medical Holding Corporation

    SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

    11/14/24 5:35:52 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

    11/14/24 4:20:10 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASNS
    $FRGT
    $ICU
    $REPL
    Financials

    Live finance-specific insights

    View All

    SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

    DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, March 25, 2026, at 4:30 p.m. ET / 2:30 p.m. MT  Webcast:The live webcast and replay can be found here.  Register for the call:Preregistration is required to attend the live call and can be accessed h

    3/18/26 4:05:00 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    The J.M. Smucker Co. Announces Fiscal 2026 Third Quarter Results

    ORRVILLE, Ohio, Feb. 26, 2026 /PRNewswire/ -- The J.M. Smucker Co. (NYSE:SJM) today announced results for the third quarter ended January 31, 2026, of its 2026 fiscal year. Financial results for the third quarter of fiscal year 2026 reflect the divestiture of certain Sweet Baked Snacks value brands on March 3, 2025, and the divestiture of the Voortman® business on December 2, 2024. All comparisons are to the third quarter of the prior fiscal year, unless otherwise noted.EXECUTIVE SUMMARYNet sales was $2.3 billion, an increase of $153.4 million, or 7 percent. Net sales excluding the divestitures and foreign currency exchange increased 8 percent.Net loss per diluted share was $6.79, reflecting

    2/26/26 7:00:00 AM ET
    $SJM
    Packaged Foods
    Consumer Staples

    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motionBysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.

    2/11/26 4:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care